An update on novel approaches for migraine prevention and treatment
Migraine is a condition that is characterized by headache of changing intensity, often accompanied by nausea and sensitivity to light and sound. The conventional therapies used for the management of migraine are not very successful because of the poor efficacy and tolerance. For the acute treatment of migraine, analgesics, combinations of analgesics with caffeine, ergotamines, and the triptans are used.
One of the recent review studies have tried to list out the successful new approaches for the treatment of acute migraine. Target calcitonin gene-related peptide (CGRP) and serotonin (5-hydroxytryptamine, 5-HT1F) receptors have gained attention as successful therapies for migraine. Few other approaches targeting the transient receptor potential vanilloid (TRPV1) receptor, glutamate, GABAA receptors, or a combination of 5-HT1B/1D receptors and neuronal nitric oxide synthesis have been inspected but were not found effective in clinical trials so far.
The most favorable approaches for migraine prevention include humanised antibodies against CGRP or the CGRP receptor. Non-invasive and invasive neuromodulation approaches also holds a good potential as both acute and preventive therapies, however future studies are desired in order to state suitable patients for such therapies and optimal procedures for their use.